News & Presentations

News Releases

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
Sep 06, 2023
Tarsus to Present at Upcoming Investor Conferences
Aug 30, 2023
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Aug 24, 2023
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
Aug 10, 2023
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
Aug 01, 2023
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
Jul 31, 2023
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
Jul 25, 2023
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
Jun 12, 2023
Tarsus to Present at the Jefferies Global Healthcare Conference
Jun 05, 2023
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
May 09, 2023

Presentations